These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pathogenesis of ascites in cirrhosis. Arroyo V; Badalamenti S; Ginès P Minerva Med; 1987 May; 78(10):645-50. PubMed ID: 3587709 [No Abstract] [Full Text] [Related]
5. [Functional insufficiency in chronic liver disease patients. The hepatorenal syndrome]. Gentilini P; Laffi G Minerva Med; 1987 May; 78(10):651-4. PubMed ID: 3587710 [No Abstract] [Full Text] [Related]
6. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Arroyo V; Ginès P; Gerbes AL; Dudley FJ; Gentilini P; Laffi G; Reynolds TB; Ring-Larsen H; Schölmerich J Hepatology; 1996 Jan; 23(1):164-76. PubMed ID: 8550036 [No Abstract] [Full Text] [Related]
7. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis. Gentilini P; Laffi G; La Villa G; Raggi VC Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019 [TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of ascites in cirrhosis and portal hypertension. Heneghan MA; Harrison PM Med Sci Monit; 2000; 6(4):807-16. PubMed ID: 11208415 [TBL] [Abstract][Full Text] [Related]
10. [Physiopathology of refractory ascites and the hepatorenal syndrome]. Arroyo V Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916 [No Abstract] [Full Text] [Related]
11. [Pathogenesis and therapy of ascites in liver cirrhosis]. Nilius R Gastroenterol J; 1991; 51(3-4):97-102. PubMed ID: 1811663 [TBL] [Abstract][Full Text] [Related]
12. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. Arroyo V; Terra C; Ginès P J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801 [No Abstract] [Full Text] [Related]
13. Review article: Management of ascites and associated complications in patients with cirrhosis. Kuiper JJ; de Man RA; van Buuren HR Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():183-93. PubMed ID: 18081661 [TBL] [Abstract][Full Text] [Related]
14. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Karwa R; Woodis CB Ann Pharmacother; 2009 Apr; 43(4):692-9. PubMed ID: 19299324 [TBL] [Abstract][Full Text] [Related]
15. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. Martin PY; Ginès P; Schrier RW N Engl J Med; 1998 Aug; 339(8):533-41. PubMed ID: 9709047 [No Abstract] [Full Text] [Related]
16. Circulatory function and hepatorenal syndrome in cirrhosis. Ruiz-del-Arbol L; Monescillo A; Arocena C; Valer P; Ginès P; Moreira V; Milicua JM; Jiménez W; Arroyo V Hepatology; 2005 Aug; 42(2):439-47. PubMed ID: 15977202 [TBL] [Abstract][Full Text] [Related]
17. [Natural course and physiopathology of ascites in the cirrhotic patient]. Bernardi M; Colantoni A; Caraceni P; Sica G; Trevisani F Ann Ital Med Int; 1996 Oct; 11 Suppl 2():30S-38S. PubMed ID: 9004818 [TBL] [Abstract][Full Text] [Related]
18. [Pharmacological treatment of ascites and hepatorenal syndrome]. Gülberg V; Gerbes AL Dtsch Med Wochenschr; 2003 Feb; 128(8):375-7. PubMed ID: 12594623 [No Abstract] [Full Text] [Related]